Checkpoint Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/A$ (N/A)
Beta 1.62
Market capitalization 56.28M
Operating cash flow -51.73M
ESG Scores unknown

Company description

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 6.72M -5.04M -833k 18.77M
Total Cashflows From Investing Activities
Net Borrowings
Total Cash From Financing Activities 28.57M 25.45M 31.25M 40.27M
Change To Operating Activities 485k 509k -941k 828k
Issuance Of Stock 30.99M 27.57M 33.28M 41.28M
Net Income -36.37M -24.71M -23.08M -56.67M
Change In Cash 2.77M 4.08M 14.7M 13.96M
Effect Of Exchange Rate
Total Cash From Operating Activities -25.8M -21.37M -16.55M -26.31M
Depreciation
Change To Account Receivables -1.2M 1.51M 6k 3k
Other Cashflows From Financing Activities -2.42M -2.12M -2.03M -1.01M
Change To Netincome 4.56M 6.37M 8.3M 10.77M
Capital Expenditures

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -36.37M -24.71M -23.08M -56.67M
Net Income -36.37M -24.71M -23.08M -56.67M
Selling General Administrative 6.59M 7.23M 7.92M 8.54M
Gross Profit -30.15M -17.62M -15.28M -48.19M
Ebit -36.74M -24.85M -23.2M -56.72M
Operating Income -36.74M -24.85M -23.2M -56.72M
Interest Expense
Income Tax Expense
Total Revenue 3.51M 1.71M 1.07M 268k
Cost Of Revenue 33.65M 19.32M 16.35M 48.45M
Total Other Income ExpenseNet 373k 136k 120k 53k
Net Income From Continuing Ops -36.37M -24.71M -23.08M -56.67M
Net Income Applicable To Common Shares -36.37M -24.71M -23.08M -56.67M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 13.09M 8.12M 7.22M 25.98M
Total Stockholder Equity 11.81M 18.85M 35.38M 29.75M
Other Current Liabilities 377k 268k 385k 233k
Total Assets 24.9M 26.97M 42.6M 55.73M
Common Stock 4k 6k 7k 9k
Other Current Assets
Retained Earnings -95.4M -120.11M -143.19M -199.86M
Treasury Stock 1.75M 2.51M 4.62M 6.6M
Cash 22M 26.08M 40.77M 54.73M
Total Current Liabilities 13.09M 8.12M 7.22M 25.98M
Other Stockholder Equity 1.75M 2.51M 4.62M 6.6M
Property, Plant, and Equipment
Total Current Assets 24.9M 26.97M 42.6M 55.73M
Net Tangible Assets 11.81M 18.85M 35.38M 29.75M
Net Receivables 1.53M 26k 20k 17k
Accounts Payable 9.75M 3.08M 3.44M 16.14M


Insider Transactions

Here are the insider transactions of stock shares related to Checkpoint Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
OLIVIERO JAMES F IIISale at price 1.09 - 1.11 per share.D2022-06-23Chief Executive Officer276k
WEISS MICHAEL SStock Award(Grant) at price 0.00 per share.I2022-06-16Director47.62k
SALZMAN BARRY MStock Award(Grant) at price 0.00 per share.D2022-06-16Director47.62k
HERSKOWITZ NEILStock Award(Grant) at price 0.00 per share.D2022-06-16Director47.62k
BECHON CHRISTIANStock Award(Grant) at price 0.00 per share.D2022-06-16Director47.62k
BOILEN SCOTTStock Award(Grant) at price 0.00 per share.D2022-06-16Director47.62k
ROSENWALD LINDSAY AStock Award(Grant) at price 0.00 per share.D2022-06-16Director47.62k
OLIVIERO JAMES F IIISale at price 1.51 - 1.79 per share.D2022-04-13Chief Executive Officer121.64k
GRAY WILLIAM GARRETTSale at price 1.89 per share.D2022-03-10Chief Financial Officer38.2k
GRAY WILLIAM GARRETTSale at price 2.51 per share.D2022-02-01Chief Financial Officer37.06k
OLIVIERO JAMES F IIIStock Award(Grant) at price 0.00 per share.D2022-01-31Chief Executive Officer455k
GRAY WILLIAM GARRETTStock Award(Grant) at price 0.00 per share.D2022-01-31Chief Financial Officer137k
WEISS MICHAEL SStock Award(Grant) at price 0.00 per share.I2021-06-10Director16.5k
SALZMAN BARRY MStock Award(Grant) at price 0.00 per share.D2021-06-10Director16.5k
HERSKOWITZ NEILStock Award(Grant) at price 0.00 per share.D2021-06-10Director16.5k
BECHON CHRISTIANStock Award(Grant) at price 0.00 per share.D2021-06-10Director16.5k
BOILEN SCOTTStock Award(Grant) at price 0.00 per share.D2021-06-10Director16.5k
ROSENWALD LINDSAY AStock Award(Grant) at price 0.00 per share.D2021-06-10Director16.5k
OLIVIERO JAMES F IIISale at price 3.42 - 3.51 per share.D2021-02-05Chief Executive Officer118.79k
GRAY WILLIAM GARRETTSale at price 3.66 per share.D2021-02-04Chief Financial Officer26.32k
OLIVIERO JAMES F IIIStock Award(Grant) at price 0.00 per share.D2021-01-06Chief Executive Officer539k
GRAY WILLIAM GARRETTStock Award(Grant) at price 0.00 per share.D2021-01-06Chief Financial Officer151k
GRAY WILLIAM GARRETTSale at price 2.79 per share.D2020-12-22Chief Financial Officer2.41k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Checkpoint Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Checkpoint Therapeutics Inc

Here is the result of two systematic investment strategies applied to Checkpoint Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Checkpoint Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Checkpoint Therapeutics Inc:

Checkpoint Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 63.61% on the backtest period.

Performance at glance

Performance

63.61 %

Latent gain

1113.68 $

Invested capital

1750.82 $

Annualized return

15.51 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Checkpoint Therapeutics Inc

This is the result of two momentum investment strategies applied to Checkpoint Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Checkpoint Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Checkpoint Therapeutics Inc:

Checkpoint Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 82.73% of return on Checkpoint Therapeutics Inc. That represents 3097.86$ of latent gain with 3744.64$ of employed capital.
  • The second momentum investment strategy would give 91.84% of return on Checkpoint Therapeutics Inc. That represents 3670.5$ of latent gain with 3996.5$ of employed capital.
Performance at glance (1Q Momentum)

Performance

82.73 %

Latent gain

3097.86 $

Invested capital

3744.64 $

Annualized return

55.8 %
Performance at glance (2Q Momentum)

Performance

91.84 %

Latent gain

3670.5 $

Invested capital

3996.5 $

Annualized return

25.37 %

Momentum equity curve on Checkpoint Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Checkpoint Therapeutics Inc:

Checkpoint Therapeutics Inc momentum equity

Note: the dividends potentially given by Checkpoint Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Checkpoint Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Checkpoint Therapeutics Inc since the beginning:

Checkpoint Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Checkpoint Therapeutics Inc

Buy the dip entry openings on Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc

The performance achieved by the robo-advisor on Checkpoint Therapeutics Inc is 117.17%. That represents 880.5$ of latent gain with 751.5$ of employed capital. The following chart shows Checkpoint Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Checkpoint Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

117.17 %

Latent gain

880.5 $

Invested capital

751.5 $

Annualized return

55.8 %

Equity curve of the strategy applied to Checkpoint Therapeutics Inc

The following chart shows the result of the investment strategy applied to Checkpoint Therapeutics Inc:

Checkpoint Therapeutics Inc

Note: the dividends potentially given by Checkpoint Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Checkpoint Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Checkpoint Therapeutics Inc:

Checkpoint Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Checkpoint Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Checkpoint Therapeutics Inc.

Equity curve comparison on Checkpoint Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Checkpoint Therapeutics Inc investment strategy comparison

Employed capital comparison on Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc investment comparison

Performance comparison on Checkpoint Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 63.61% 1113.68$ 1750.82$ 15.51%
Momentum 1 quarter 82.73% 3097.86$ 3744.64$ 21.43%
Momentum 2 quarters 91.84% 3670.5$ 3996.5$ 25.37%
Non-directional 117.17% 880.5$ 751.5$ 55.8%
Annualized return comparison

Automatic investment

15.51 %

Momentum 1Q

25.37 %

Momentum 2Q

25.37 %

Non-directional

55.8 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Checkpoint Therapeutics Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months


Note: The algorithm computes the probability of correlation between Checkpoint Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Checkpoint Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Checkpoint Therapeutics Inc
Country United States
City Waltham
Address 95 Sawyer Road
Phone 781 652 4500
Website www.checkpointtx.com
FullTime employees 14
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker CKPT
Market www.nasdaq.com

Checkpoint Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown